Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process

Hematol Oncol. 1990 Jul-Aug;8(4):215-27. doi: 10.1002/hon.2900080406.

Abstract

Some patients with cerebriform T-cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transformation at the initial diagnosis while the median time from diagnosis to transformation in the other 13 patients was 16 months (range: 3 months-6 years). Thirteen had transformation extracutaneously: lymph nodes (eight), central nervous system (two), and other extranodal sites (three). T cell markers were identified in all cases; of 15 cases with complete phenotypes, there were eight T-helper, three T-suppressor, and four aberrant T phenotypes. Serology for human T-leukemia virus-I (HTLV-I) was negative in eight patients tested. Median survival from diagnosis was 27 months compared to 53 months in 53 patients without transformation (p = 0.003). Despite combination chemotherapy in 12 patients following transformation, median survival after transformation was 12 months and only 7 months with extracutaneous disease. The likelihood of transformation could not be predicted by the initial histology, immunophenotype, or stage of disease.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Cell Transformation, Neoplastic / pathology*
  • Child
  • Child, Preschool
  • HIV / isolation & purification
  • Human T-lymphotropic virus 1 / isolation & purification
  • Humans
  • Infant
  • Lymph Nodes / pathology
  • Lymphoma, Large B-Cell, Diffuse / immunology
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / mortality
  • Lymphoma, T-Cell / pathology*
  • Lymphoma, T-Cell / therapy
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Middle Aged